These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24053416)

  • 21. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease.
    Sethi S; Sethi R; Eschberger K; Lobbins P; Cai X; Grant BJ; Murphy TF
    Am J Respir Crit Care Med; 2007 Aug; 176(4):356-61. PubMed ID: 17478618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inspiratory capacity and forced expiratory volume in the first second in exacerbation of chronic obstructive pulmonary disease.
    Yetkin O; Gunen H
    Clin Respir J; 2008 Jan; 2(1):36-40. PubMed ID: 20298302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying patients at risk of late recovery (≥ 8 days) from acute exacerbation of chronic bronchitis and COPD.
    Anzueto A; Miravitlles M; Ewig S; Legnani D; Heldner S; Stauch K
    Respir Med; 2012 Sep; 106(9):1258-67. PubMed ID: 22749710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.
    Seemungal TA; Donaldson GC; Bhowmik A; Jeffries DJ; Wedzicha JA
    Am J Respir Crit Care Med; 2000 May; 161(5):1608-13. PubMed ID: 10806163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of an action plan with ongoing support by a case manager on exacerbation-related outcome in patients with COPD: a multicentre randomised controlled trial.
    Trappenburg JC; Monninkhof EM; Bourbeau J; Troosters T; Schrijvers AJ; Verheij TJ; Lammers JW
    Thorax; 2011 Nov; 66(11):977-84. PubMed ID: 21785156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.
    Yu AP; Yang H; Wu EQ; Setyawan J; Mocarski M; Blum S
    J Med Econ; 2011; 14(3):315-23. PubMed ID: 21500975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
    Kuna P; Jenkins M; O'Brien CD; Fahy WA
    Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT).
    Mackay AJ; Donaldson GC; Patel AR; Singh R; Kowlessar B; Wedzicha JA
    Eur Respir J; 2014 Mar; 43(3):735-44. PubMed ID: 23988767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor analysis in predominantly severe COPD: identification of disease heterogeneity by easily measurable characteristics.
    Postma DS; Anzueto AR; Jenkins C; Make BJ; Similowski T; Östlund O; Eriksson GS; Calverley PM
    Respir Med; 2013 Dec; 107(12):1939-47. PubMed ID: 23953956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between pulmonary function and physical activity in daily life in patients with COPD.
    Pitta F; Takaki MY; Oliveira NH; Sant'anna TJ; Fontana AD; Kovelis D; Camillo CA; Probst VS; Brunetto AF
    Respir Med; 2008 Aug; 102(8):1203-7. PubMed ID: 18573647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study.
    Garcia-Aymerich J; Lange P; Benet M; Schnohr P; Antó JM
    Am J Respir Crit Care Med; 2007 Mar; 175(5):458-63. PubMed ID: 17158282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal follow-up of systemic inflammation after acute exacerbations of COPD.
    Groenewegen KH; Dentener MA; Wouters EF
    Respir Med; 2007 Nov; 101(11):2409-15. PubMed ID: 17644367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resting and ADL-induced dynamic hyperinflation explain physical inactivity in COPD better than FEV1.
    Lahaije AJ; van Helvoort HA; Dekhuijzen PN; Vercoulen JH; Heijdra YF
    Respir Med; 2013 Jun; 107(6):834-40. PubMed ID: 23514950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are depressive symptoms related to physical inactivity in chronic obstructive pulmonary disease?
    Venkata A; DeDios A; ZuWallack R; Lahiri B
    J Cardiopulm Rehabil Prev; 2012; 32(6):405-9. PubMed ID: 23011487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity levels after pulmonary rehabilitation - what really happens?
    Dyer CA; Harris ND; Jenkin E; Langley-Johnson C; Lewis R; Taylor GJ; Gruffydd-Jones K
    Physiotherapy; 2013 Sep; 99(3):228-32. PubMed ID: 23219642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pain and physical performance in people with COPD.
    HajGhanbari B; Garland SJ; Road JD; Reid WD
    Respir Med; 2013 Nov; 107(11):1692-9. PubMed ID: 23845881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.